AU2018210174B2 - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases - Google Patents

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases Download PDF

Info

Publication number
AU2018210174B2
AU2018210174B2 AU2018210174A AU2018210174A AU2018210174B2 AU 2018210174 B2 AU2018210174 B2 AU 2018210174B2 AU 2018210174 A AU2018210174 A AU 2018210174A AU 2018210174 A AU2018210174 A AU 2018210174A AU 2018210174 B2 AU2018210174 B2 AU 2018210174B2
Authority
AU
Australia
Prior art keywords
pen
lys
phe
nal
meleu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018210174A
Other languages
English (en)
Other versions
AU2018210174A1 (en
Inventor
Ashok Bhandari
Gregory BOURNE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protagonist Therapeutics Inc
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of AU2018210174A1 publication Critical patent/AU2018210174A1/en
Application granted granted Critical
Publication of AU2018210174B2 publication Critical patent/AU2018210174B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018210174A 2017-01-18 2018-01-18 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases Active AU2018210174B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762447778P 2017-01-18 2017-01-18
US62/447,778 2017-01-18
PCT/US2018/014257 WO2018136646A1 (en) 2017-01-18 2018-01-18 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Publications (2)

Publication Number Publication Date
AU2018210174A1 AU2018210174A1 (en) 2019-07-25
AU2018210174B2 true AU2018210174B2 (en) 2022-04-07

Family

ID=62908287

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018210174A Active AU2018210174B2 (en) 2017-01-18 2018-01-18 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Country Status (6)

Country Link
US (2) US20200207822A1 (https=)
EP (1) EP3570864B1 (https=)
JP (3) JP2020505352A (https=)
AU (1) AU2018210174B2 (https=)
CA (1) CA3049889A1 (https=)
WO (1) WO2018136646A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2968443T3 (da) 2013-03-15 2021-12-06 Protagonist Therapeutics Inc Hepcidinanaloger og anvendelser deraf
PT3143037T (pt) 2014-05-16 2021-09-24 Protagonist Therapeutics Inc Antagonistas peptídicos tioéter de integrina alfa4beta7
US9624268B2 (en) 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
KR20170108936A (ko) 2014-10-01 2017-09-27 프로타고니스트 테라퓨틱스, 인코포레이티드 신규한 α4β7 펩타이드 단량체 및 이량체 길항제
EP3201217A4 (en) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP4067368A1 (en) 2016-06-01 2022-10-05 Athira Pharma, Inc. Compounds
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
TW202019948A (zh) 2018-07-12 2020-06-01 美商領導醫療有限公司 介白素-23受體之肽抑制劑及其治療發炎疾病之用途
CN114341161A (zh) * 2019-07-10 2022-04-12 领导医疗有限公司 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
TW202116793A (zh) * 2019-07-10 2021-05-01 美商領導醫療有限公司 介白素-23受體之肽抑制劑及其於治療發炎疾病的用途
HRP20250769T1 (hr) * 2020-01-15 2025-08-29 Janssen Biotech, Inc. Peptidni inhibitori receptora za interleukin-23 i njihova uporaba u liječenju upalnih bolesti
AU2021209086A1 (en) * 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
WO2023288019A2 (en) 2021-07-14 2023-01-19 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor
CA3226539A1 (en) * 2021-07-14 2023-01-19 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor
CN118354781A (zh) 2021-12-01 2024-07-16 西兰制药公司 白介素-23受体的肽抑制剂
CA3260606A1 (en) 2022-06-30 2024-01-04 Sanofi NEW PEPTIDES FOR USE AS SELECTIVE IL-23 RECEPTOR ANTAGONISTS
CN120019064A (zh) * 2022-07-14 2025-05-16 詹森药业有限公司 Il-23的环肽抑制剂
WO2024155552A1 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Formulations of lipidated peptide inhibitors of interleukin-23 receptor
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121909205A (zh) 2023-09-08 2026-04-21 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2025051920A1 (en) 2023-09-08 2025-03-13 Sanofi New peptides as selective il-23 receptor inhibitors
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026057052A1 (zh) * 2024-09-14 2026-03-19 深圳信立泰药业股份有限公司 一种il-23受体抑制剂及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200064357A1 (en) * 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166138A1 (en) * 2002-02-21 2003-09-04 Todd Kinsella Cyclic peptides and analogs useful to treat allergies
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9605027B2 (en) * 2011-06-14 2017-03-28 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9624268B2 (en) * 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
HK1257747A1 (zh) 2015-07-15 2019-10-25 Protagonist Therapeutics Inc. 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200064357A1 (en) * 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation

Also Published As

Publication number Publication date
JP2025162551A (ja) 2025-10-27
JP2023014346A (ja) 2023-01-26
US20240132558A1 (en) 2024-04-25
WO2018136646A1 (en) 2018-07-26
EP3570864C0 (en) 2026-02-18
EP3570864A4 (en) 2020-12-30
JP7819087B2 (ja) 2026-02-24
EP3570864A1 (en) 2019-11-27
JP2020505352A (ja) 2020-02-20
AU2018210174A1 (en) 2019-07-25
CA3049889A1 (en) 2018-07-26
US20200207822A1 (en) 2020-07-02
EP3570864B1 (en) 2026-02-18

Similar Documents

Publication Publication Date Title
AU2018210174B2 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20240199700A1 (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US12552836B2 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US12018057B2 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11041000B2 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146458A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA2991984A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20260116921A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 18 JAN 2025 TO 18 AUG 2025 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 18 AUG 2025